Medigen shares COVID vaccine tech with WHO in world-first deal

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Medigen shares COVID vaccine tech with WHO in world-first deal

covid.jpg

The Taiwanese biotech firm is the first commercial entity to share IP and know-how via a WHO pool set up in 2020

Taiwanese biotech firm Medigen yesterday, August 29, became the first commercial entity to share COVID vaccine technology with the World Health Organization.

Medigen’s vaccine unit was among three licensors to share tech via the WHO’s COVID-19 Technology Access Pool (C-TAP) in new deals, alongside research institutes in Spain and Chile.

The deals involve the licensing of patents as well as the sharing of know-how, materials, and clinical data.

More than three million doses of Medigen's vaccine have been administered across seven countries.

The Spanish National Research Council (CSIC) agreed to share access to a COVID vaccine prototype while the University of Chile will share tech for a COVID antibody test.

“COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it,” said Tedros Adhanom Ghebreyesus, WHO director-general.

“I am grateful to the leadership shown by those licence holders who have contributed technology,” he added.

Charles Chen, CEO of Medigen Vaccine Biologics, said solidarity and cooperation were the foundations of an effective pandemic response.

“This is not just about COVID-19; it is about setting a precedent for future global health challenges.

“We hope to inspire other organisations to follow suit,” Chen said.

Previously, only two public health institutes – the CSIC, which signed a separate deal with C-TAP in 2021, and the US National Institute of Health – had agreed to license tech through the WHO pool since it was set up in 2020.

Access to medicine campaigners welcomed the news as a “significant step” and urged major COVID vaccine makers to share their intellectual property.

Julia Kosgei, policy co-lead for campaign group the People’s Vaccine Alliance, said: “By sharing technology with C-TAP, these organisations are placing the needs of humanity over the narrow perception of profit and self-interest that has so far plagued the pharmaceutical industry.”

“It is shameful that, despite receiving unprecedented public funding and advance purchases, not even one of the major pharmaceutical companies has shared vaccine technology with C-TAP,” Kosgei added.

Negotiations for a pandemic prevention treaty, including potential reforms to the global intellectual property system, are currently ongoing at the WHO.

more from across site and SHARED ros bottom lb

More from across our site

Florina Firaru discusses making new connections, the art of flower arranging, and the biggest misconception about IP
The firm, which appointed three IP partners from A&O Shearman, wants to develop a tier one practice in Europe
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
A host of law firms from across Europe and beyond helped bring the streaming technology dispute to a close
Hugues Derème, director general of the Benelux IP Office, unveils his vision for the region, how to improve IP awareness, and use of AI
A copyright win for AI firm Anthropic and a new executive order against law firm Jenner & Block were also among the top talking points this week
A principal at Schwegman Lundberg & Woessner explains how AI tools, including DeepIP, can position the firm to help clients
The firm explains why AI-empowered data analytics could make it a more efficient advocate for its clients
Penelope Aspinall, of IP wellbeing charity Jonathan’s Voice, explains why managers should take a three-tiered approach to looking after workers’ mental health
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
Gift this article